Compare Biogen Inc (BIIB) vs CleanSpark Inc (CLSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs CleanSpark Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while CleanSpark Inc trades at $12.17 (market cap $2.96B). The key difference: Biogen Inc is far larger — about 10.2× CleanSpark Inc's market cap, and Biogen Inc is trading nearer its 52-week high, CleanSpark Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | CLSK | |
|---|---|---|
Market Cap | $30.13B | $2.96B |
Sector | Health | Technology |
52-Week High | $216.63 | $23.20 |
52-Week Low | $128.93 | $8.18 |
Enterprise Value | $37.20B | $3.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
CleanSpark (CLSK) trades at $12.08, up 4.23% today but facing bearish technical signals with recent earnings misses. The company reported a Q3 2026 loss of $0.89 per share versus expectations of -$0.47, continuing a trend of negative profitability despite securing a significant $6.6 billion AI data center lease. Analyst sentiment remains strongly bullish with 11 buy ratings and a $24.13 consensus price target, representing 100% upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with strong institutional support but significant execution challenges. While the AI infrastructure pivot offers long-term growth potential, near-term profitability concerns and negative cash flow create substantial volatility. Investors must weigh the disconnect between bullish analyst coverage and persistent earnings underperformance against the company's strategic repositioning in digital infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →
